Categories
World

Brazil’s P1 coronavirus variant is worrying and may become more dangerous, study finds

Brazil’s P1 coronavirus variant, behind a deadly COVID-19 surge in the Latin American country has raised alarm overseas and is mutating in ways that could make it better able to evade antibodies, according to scientists studying the virus.

Research conducted by the public health institute Fiocruz into the variants circulating in Brazil found mutations in the spike region of the virus that is used to enter and infect cells.

Those changes, the scientists said, could make the virus more resistant to vaccines, which target the spike protein with potentially grave implications for the severity of the outbreak.




“We believe it’s another escape mechanism the virus is creating to evade the response of antibodies,” said Felipe Naveca, one of the authors of the study and part of Fiocruz in the Amazon city of Manaus, where the P1 variant is believed to have originated.

Naveca said the changes appeared to be similar to the mutations seen in the even more aggressive South African variant, against which studies have shown some vaccines have substantially reduced efficacy.

“This is particularly worrying because the virus is continuing to accelerate in its evolution,” he added.



Studies have shown the P1 variant to be as much as 2.5 times more contagious than the original coronavirus and more resistant to antibodies.

On Tuesday, France suspended all flights to and from Brazil in a bid to prevent the variant’s spread as Latin America’s largest economy becomes increasingly isolated.

The variant, which has quickly become dominant in Brazil, is thought to be a large factor behind a massive second wave that has brought the country’s death toll to over 350,000, the highest in the world behind the United States.

Brazil’s outbreak is also increasingly affecting younger people, with hospital data showing that in March more than half of all patients in intensive care were aged 40 or younger.

While vaccines developed by AstraZeneca and China’s Sinovac, have proven effective against the P1 Brazilian variant, further mutations could put that at risk.